Wave 3 of the UK Government’s science and innovation audits (SIAs) have been published today, identifying a number of strengths in different industries across the country — including precision medicine innovation in Scotland, led by the University of Glasgow.
Glasgow UK, 12 March 2019 – REPROCELL Europe Ltd (REPROCELL), a UK-based human tissue research company, today announced a strategic partnership with Medicines Discovery Catapult.
BELTSVILLE, MD. — REPROCELL Inc. and Fox Chase, Ltd., a member of the Fox Chase Cancer Center family of organizations, have formed a joint venture to begin operations of multi-site biosample repository facilities globally. The new Delaware-based joint venture company, Biorepository LLC, will act as a hub to manage its global subsidiaries, and its first subsidiary will be established in India in March.
The REPROCELL group has signed a non-exclusive distributorship agreement with RUITAI Biotechnology (Shanghai) Ltd to distribute REPROCELL’s products in China.
REPROCELL announced today we have launched a cutting-edge genome editing service utilizing next-generation CRISPR/Cas9 technology, called SNIPER. This service is offered in collaboration with GenAhead Bio Inc. (Kanagawa, Japan; hereinafter referred to as “GenAhead”). GenAhead is a venture company established by a team of experts in genetic modification technology. Since April 2018, REPROCELL has had a strategic investment in GenAhead.
San Diego, CA, USA – Steminent Biotherapeutics Inc. (“Steminent” or “Company”) a private, clinical-stage cell-therapy company with offices in Taiwan, San Diego and Shanghai, is pleased to announce that the Clinical Trial Notification (“CTN”), submitted by their Japan partner, REPROCELL, to the Japan Pharmaceuticals and Medical Device Agency (“PMDA”) for a Stemchymal® SCA Phase II clinical trial for Polyglutamine Spinocerebellar Ataxia (“PolyQ SCA”) has been approved. This is another key milestone for Steminent’s international Stemchymal® SCA Phase II clinical development program with trials now moving ahead in Taiwan, US, and Japan.
REPROCELL India (formerly BioServe Biotechnologies) is a state-of-the-art biotechnology company with a mission to serve the life sciences research ecosystem.
Human Tissues, Stem Cells, Human Genome Sequencing, Bioinformatics, Global Expertise
REPROCELL Europe’s CEO, Dr David Bunton, was part of last week's trade mission to China undertaken by the Scottish First Minister, the Rt. Hon. Nicola Sturgeon MSP.
Sign up to receive information from REPROCELL about our products, services, applications, promotions, and news (includes a weekly blog update email).
© 2019 REPROCELL Inc. All rights reserved.
REPROCELL USA Inc. Registered office REPROCELL USA Inc., 9000 Virginia Manor Road, Suite 207, Beltsville, 20705, USA, Registered in United States